碳酸锂维持治疗双相情感障碍的剂量选择

碳酸锂维持治疗双相情感障碍的剂量选择王相立孙士田麻爱华碳酸锂预防治疗躁狂和抑郁均具较好效果，但仍有部分病人在碳酸锂维持治疗期间复发。为探讨这是否与维持治疗的药物剂量有关，我们对不同剂量碳酸锂的抗复发效果进行了３年随访研究，现将结果报道于下。１．一般资...     

碳酸锂致粘液性水肿2例浅析

碳酸锂致粘液性水肿２例浅析浙江衢州市精神病医院程祥光，徐华　报道２例年龄为１８～２４岁，既往除“情感异常”外，无其他躯体病史；体检及神经系统检查均无阳性体征发现，精神检查为典型躁狂状态，入院诊断均为“双相情感障碍－躁狂相”；用碳酸锂等药物给予治疗。治...     

碳酸锂所致皮疹反应2例报告

碳酸锂所致皮疹反应２例报告四川省攀枝花市第三人民医院（６１７０６１）李培轩，罗明例１，男，２４岁，教师。住院诊断情感性精神障碍－躁狂发作。给予碳酸锂治疗，最大剂量１ｇ／日，服用９月后，突然四肢及胸腹部出现呈片状分布的针尖样、红色，压之不褪色的大量皮疹...     

托吡酯治疗双相障碍躁狂发作的疗效及对患者体重的影响

国外报道托吡酯（topirimate,商品名妥泰）可用于双相和分裂情感障碍患者[1～5]。国内报道其具有与碳酸锂相似的抗躁狂疗效[6],故我们用它治疗躁狂发作41例。     

卡马西平致阴茎皮疹、肿痛一例报告

卡马西平致阴茎皮疹、肿痛一例报告云南省大理州精神卫生中心（６７１０００）刘成立患者，男性，２３岁。诊断：双相情感障碍（躁狂相），病程６年，第四次住院。既往无药物过敏史。入院体检神经系统检查未发现异常，血、尿常规检查正常。考虑前三次住院所用碳酸锂治疗，...     

维拉帕米（异搏定）与碳酸锂治疗躁狂发作对照研究＊

试用维拉帕米(异搏定)治疗情感性障碍躁狂发作,以碳酸锂作对照。异搏定的有效率为71.4%;疗效与碳酸锂相似,而心脏副反应较重。     

齐拉西酮合并碳酸锂治疗双相情感障碍躁狂发作的疗效及安全性

目的 评价齐拉西酮合并碳酸锂治疗双相情感障碍躁狂发作的疗效及安全性.方法 将2018年2月～2019年3月期间我院收治的70例双相情感障碍躁狂发作患者分成对照组和研究组,每组35例.对照组单用碳酸锂治疗;研究组联合碳酸锂与齐拉西酮治疗.对比观察两组患者的临床疗效.结果 研究组总有效率97.1％(34/35)高于对照组8...     

卡马西平、碳酸锂对双相情感性障碍预防效果对照研究

卡马西平、碳酸锂对双相情感性障碍预防效果对照研究刘兰芬赵贵芳宋振铎本研究对卡马西平与碳酸锂对双相情感性障碍的预防效果进行对照观察，系１９８７年１月～１９８９年１２月符合ＣＣＭＤ—２诊断标准的住院病例，经卡马西平或碳酸锂治愈出院，并以同药维持治疗者。３...     

卡马西平,碳酸锂预防治疗抑郁症的对照研究

对７２例频发的单相抑郁症和双相情感障碍抑郁相病人，采用卡马西平或碳酸锂进行３年预防复发的前瞻性研究。结果发现卡巴西平有效率为６４．１０％，碳酸锂为６０．６１％。卡马西平的副反应发生率略低于碳酸锂。     

碳酸锂联用拉莫三嗪对双相情感障碍快速循环型的疗效研究

目的 探讨碳酸锂联用拉莫三嗪对双相情感障碍快速循环型的疗效。方法 将40例快速循环型患者随机分为实验组和对照组,每组20例。实验组选用碳酸锂联用拉莫三嗪联合治疗,对照组单用碳酸锂治疗,分别于治疗前、治疗第2周、第4周和第6周选用大体评定量表（CGI）和简明精神病评定量表（BPRS）予以评定。结果 实验组在治疗第2周、第4周和第6周CGI评定总有效率分别为27％、48％、76％,显著高于对照组,BPRS评分显著低于对照组。结论 碳酸锂联用拉莫三嗪对双相情感障碍快速循环型具有良好的疗效。     

A patient of myasthenia gravis complicated by lichen planus 9 years after thymectomy]

We report a 39-year-old woman with myasthenia gravis (MG) complicated by lichen planus, elevated liver enzymes of unknown cause and mucosal lesions of the colon and anus. Although the etiology of lichen planus is uncertain, an autoimmune abnormality is considered to be a possible cause. Lichen planus is sometimes associated with thymoma. This patient had hyperplasia of the thymus which was surgically removed nine years prior to lichen planus development. Myasthenic symptoms worsened when the lichen planus appeared and the liver enzymes were elevated. Steroid therapy was effective for the above symptoms. The clinical course suggests that MG, lichen planus and elevated liver enzymes in this patient results from common underlying autoimmune abnormality.     

Lithium carbonate in juvenile manic-depressive illness.

A case of juvenile manic-depressive illness associated with mental retardation is reported having been treated successfully with lithium carbonate. During four years of maintenance treatment with daily doses of 600 mgs. to 900 mgs. per day of lithium carbonate, disruptive manic behavior has been controlled and a subjective leveling out of mood has allowed that patient to develop more fully her cognitive and psychomotor capacities. There was one exascerbation of disruptive behavior during the first year of treatment that was easily controlled with haloperidol together with continued lithium carbonate maintenance treatment. No measurable adverse developmental or thyroid effects have been noted. The Shaffer acquiescence scale of the MMPI correctly predicted that the patient would be a positive responder to lithium carbonate treatment.     

碳酸锂联合丙戊酸钠和利培酮治疗急性躁狂发作的对照研究

目的探讨碳酸锂分别联合丙戊酸钠和利培酮治疗急性躁狂发作的疗效和安全性。方法将94例急性躁狂发作患者随机分为两组,碳酸锂联合丙戊酸钠47例,碳酸锂联合利培酮47例,疗程均为8周。分别于治疗前及治疗后的第2、4、8周,采用躁狂量表（BRMS）评定临床疗效,治疗时出现的症状量表（TESS）评定安全性。结果碳酸锂分别联合戊酸钠和利培酮治疗急性躁狂发作的疗效相当（P〉0.05）,但前者起效快、不良反应少（P〈0.05）。结论碳酸锂联合丙戊酸钠治疗急性躁狂发作起效快、疗效显著、不良反应少,安全性高。     

碳酸锂单用与合并阿立哌唑治疗双相障碍I型躁狂发作患者的随机对照研究

目的:探讨碳酸锂单用及合并阿立哌唑治疗双相障碍I型躁狂发作患者的疗效和安全性。方法:86例门诊双相障碍I型躁狂发作患者被随机分为联合组(碳酸锂+阿立哌唑治疗)和单药组(碳酸锂单药治疗),疗程8周。分别在治疗前、治疗2、4、8周进行杨氏躁狂量表(YMRS)和汉密顿抑郁量表(HAMD)-17项评定,采用治疗中出现的症状量表(TESS)评定不良反应。结果:治疗前两组YMRS评分差异无统计学意义;治疗2、4、8周后联合组YMRS减分值明显高于对照组(P0.05或P0.01);治疗前后两组HAMD均7分;两组TESS评分差异无统计学意义。结论:碳酸锂联合阿立哌唑治疗双相障碍I型躁狂发作较单用碳酸锂起效快,症状改善更明显,且未见不良反应明显增加。     

碳酸锂联用丙戊酸钠治疗急性躁狂对照研究

目的:探讨碳酸锂联用丙戊酸钠治疗急性躁狂发作的疗效与安全性.方法:56例急性躁狂发作患者随机分成两组,分别给予碳酸锂合并丙戊酸钠(合用组)与单用碳酸锂(单用组)治疗6周.采用 Beck-Rafaelsen 躁狂量表(BRMS)评定疗效,治疗中出现的症状量表(TESS)及实验室检查评价安全性.结果:治疗结束时两组 BRMS 评分均显著降低,以合用组疗效显著较好而快.结论:碳酸锂联用丙戊酸钠治疗急性躁狂发作疗效优于单用碳酸锂,且起效快、安全性好.     

奎硫平联合碳酸锂治疗双相抑郁患者的疗效

目的:探讨奎硫平联合碳酸锂治疗双相抑郁患者的疗效和不良反应. 方法:将符合中国精神障碍分类和诊断标准第3版双相情感障碍抑郁发作诊断标准的64例患者随机分为奎硫平合并碳酸锂组(研究组)和氟西汀合并碳酸锂组(对照组).疗程8周.临床评定采用汉密尔顿抑郁量表(HAMD)及汉密尔顿焦虑量表(HAMA),用治疗中出现的症状量表(TESS)评定不良反应. 结果:治疗8周,研究组和对照组有效率分别为84.4％、78.1％,痊愈率分别为53.1％、46.9％,两组疗效差异无统计学意义(分别为t =0.10,P＞0.05;t=0.25,P＞0.05);研究组患者抑郁症状于第2周末明显改善,而焦虑症状于第1周末即显著好转;治疗8周末两组TESS评分差异无统计学意义(t=0.46,P＞0.05).结论:奎硫平联合碳酸锂治疗双相抑郁疗效明确,使用较为安全,而且起效较快.     

Downbeat nystagmus. Long-term therapy with moderate-dose lithium carbonate

Downbeat nystagmus developed in a 67-year-old hypomagnesemic woman while she was receiving lithium carbonate for depression. This nystagmus abated each time lithium carbonate therapy was withdrawn, and no alternative causes of nystagmus were demonstrated. However, this nystagmus occurred despite serum lithium carbonate levels in the nontoxic range. Total-body magnesium deficiency may have enhanced the toxic effect of lithium carbonate on cerebellomedullary connections.     

Report of a patient with lithium-related alopecia and psoriasis

In a 56-year-old woman, alopecia and psoriasis developed for the first time after treatment with lithium carbonate. These skin disorders subsequently disappeared despite continuation of the lithium treatment.     

Lithium treatment of impulsive behavior in children

Children who display sporadic unprovoked physical aggression and are refractory to usual treatment pose a difficult management problem. A group of 14 such children were matched with a control group; behaviors of both groups were observed and recorded for 3 months. The experimental group was then maintained on high doses of lithium carbonate for 3 months. Behavioral recordings were continued during this period and for 3 months after discontinuation of lithium. While on lithium, the children showed a substantial reduction in unprovoked aggressive outbursts. Because lithium was well tolerated and laboratory and clinical examinations did not show any adverse effects, it is suggested that lithium may be an important therapeutic agent in the treatment of aggression in children.